Luanne Metz

Summary

Affiliation: University of Calgary
Country: Canada

Publications

  1. ncbi request reprint Devic's neuromyelitis optica treated with intravenous gamma globulin (IVIG)
    Jacqueline Bakker
    Department of Clinical Neurosciences, University of Calgary, Calgary, AB, Canada
    Can J Neurol Sci 31:265-7. 2004
  2. ncbi request reprint Oral cannabinoids for spasticity in multiple sclerosis: will attitude continue to limit use?
    Luanne Metz
    Department of Clinical Neurosciences, Foothills Medical Center, Alberta, T2N 2T9, Calgary, Canada
    Lancet 362:1513. 2003
  3. doi request reprint Glatiramer acetate in combination with minocycline in patients with relapsing--remitting multiple sclerosis: results of a Canadian, multicenter, double-blind, placebo-controlled trial
    L M Metz
    Department of Clinical Neuroscience, University of Calgary, Calgary, Alberta, Canada
    Mult Scler 15:1183-94. 2009
  4. pmc The effect of immunomodulatory treatment on multiple sclerosis fatigue
    L M Metz
    Department of Clinical Neurosciences, University of Calgary, Alberta, Canada
    J Neurol Neurosurg Psychiatry 75:1045-7. 2004
  5. ncbi request reprint Disease management for depression in an MS clinic
    Scott B Patten
    Department of Community Health Sciences, University of Calgary, AB, Canada
    Int J Psychiatry Med 37:459-73. 2007
  6. ncbi request reprint Corpus callosum volume and interhemispheric transfer in multiple sclerosis
    L N Brown
    Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada
    Can J Neurol Sci 37:615-9. 2010
  7. ncbi request reprint Experimental models of neuroprotection relevant to multiple sclerosis
    V W Yong
    Hotchkiss Brain Institute and the Department of Clinical Neurosciences, University of Calgary, Alberta, Canada
    Neurology 68:S32-7; discussion S43-54. 2007
  8. ncbi request reprint Identifying reliable change in tactile temporal thresholds in multiple sclerosis: test-retest reliability
    L N Brown
    Department of Psychology, University of Calgary, Calgary, Alberta, Canada
    Mult Scler 12:573-7. 2006
  9. ncbi request reprint Tactile temporal thresholds detect relapse-related changes in multiple sclerosis: a preliminary study
    L N Brown
    Department of Clinical Neurosciences, University of Calgary, Alberta, Canada
    Mult Scler 11:725-7. 2005
  10. ncbi request reprint Anti-depressant use in association with interferon and glatiramer acetate treatment in multiple sclerosis
    S B Patten
    Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada T2N 4N1
    Mult Scler 14:406-11. 2008

Collaborators

Detail Information

Publications31

  1. ncbi request reprint Devic's neuromyelitis optica treated with intravenous gamma globulin (IVIG)
    Jacqueline Bakker
    Department of Clinical Neurosciences, University of Calgary, Calgary, AB, Canada
    Can J Neurol Sci 31:265-7. 2004
    ..Monthly IVIG was associated with complete cessation of relapses and significantly improved neurological status over one year of treatment...
  2. ncbi request reprint Oral cannabinoids for spasticity in multiple sclerosis: will attitude continue to limit use?
    Luanne Metz
    Department of Clinical Neurosciences, Foothills Medical Center, Alberta, T2N 2T9, Calgary, Canada
    Lancet 362:1513. 2003
  3. doi request reprint Glatiramer acetate in combination with minocycline in patients with relapsing--remitting multiple sclerosis: results of a Canadian, multicenter, double-blind, placebo-controlled trial
    L M Metz
    Department of Clinical Neuroscience, University of Calgary, Calgary, Alberta, Canada
    Mult Scler 15:1183-94. 2009
    ..We conclude that efficacy endpoints showed a consistent trend favoring combination treatment. As minocycline is a relatively safe oral therapy, further study of this combination is warranted in relapsing-remitting multiple sclerosis...
  4. pmc The effect of immunomodulatory treatment on multiple sclerosis fatigue
    L M Metz
    Department of Clinical Neurosciences, University of Calgary, Alberta, Canada
    J Neurol Neurosurg Psychiatry 75:1045-7. 2004
    ..To assess the effects of glatiramer acetate and beta interferon on fatigue in multiple sclerosis...
  5. ncbi request reprint Disease management for depression in an MS clinic
    Scott B Patten
    Department of Community Health Sciences, University of Calgary, AB, Canada
    Int J Psychiatry Med 37:459-73. 2007
    ..We explored the feasibility and effectiveness of implementing a disease management program for depression in an MS clinic...
  6. ncbi request reprint Corpus callosum volume and interhemispheric transfer in multiple sclerosis
    L N Brown
    Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada
    Can J Neurol Sci 37:615-9. 2010
    ..Judgments to bimanual stimulations require interhemispheric transfer via the CC...
  7. ncbi request reprint Experimental models of neuroprotection relevant to multiple sclerosis
    V W Yong
    Hotchkiss Brain Institute and the Department of Clinical Neurosciences, University of Calgary, Alberta, Canada
    Neurology 68:S32-7; discussion S43-54. 2007
    ..Further studies are needed to establish whether experimental neuroprotection strategies involving these mechanisms may be translated into preventing neurodegeneration in multiple sclerosis...
  8. ncbi request reprint Identifying reliable change in tactile temporal thresholds in multiple sclerosis: test-retest reliability
    L N Brown
    Department of Psychology, University of Calgary, Calgary, Alberta, Canada
    Mult Scler 12:573-7. 2006
    ..As part of an ongoing validation study of tactile temporal thresholds, the test-retest reliability of these thresholds was examined in patients with MS...
  9. ncbi request reprint Tactile temporal thresholds detect relapse-related changes in multiple sclerosis: a preliminary study
    L N Brown
    Department of Clinical Neurosciences, University of Calgary, Alberta, Canada
    Mult Scler 11:725-7. 2005
    ..Thus, tactile temporal thresholds may be a useful outcome measure in MS. Our objective was to assess whether tactile temporal thresholds reflect change during a MS relapse...
  10. ncbi request reprint Anti-depressant use in association with interferon and glatiramer acetate treatment in multiple sclerosis
    S B Patten
    Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada T2N 4N1
    Mult Scler 14:406-11. 2008
    ..This is surprising since interferons used in other clinical contexts are considered capable of causing depression. The negative results in MS could be due inadequate power in the published trials...
  11. ncbi request reprint Major depression in multiple sclerosis: a population-based perspective
    S B Patten
    Department of Community Health Sciences, University of Calgary, Alberta, Canada
    Neurology 61:1524-7. 2003
    ..To determine the prevalence of major depression in multiple sclerosis (MS) in a population-based sample controlling for nonspecific illness effects...
  12. doi request reprint 3T deep gray matter T2 hypointensity correlates with disability over time in stable relapsing-remitting multiple sclerosis: a 3-year pilot study
    Y Zhang
    Department of Clinical Neurosciences, University of Calgary, Canada
    J Neurol Sci 297:76-81. 2010
    ..Further studies are required to confirm these results in a large sample and to determine if T2 hypointensity changes in clinically active MS patients...
  13. ncbi request reprint The clinical response to minocycline in multiple sclerosis is accompanied by beneficial immune changes: a pilot study
    R K Zabad
    Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada
    Mult Scler 13:517-26. 2007
    ..The activity of matrix metalloproteinase-9 was decreased by treatment. Thus, clinical and MRI outcomes are supported by systemic immunological changes and call for further investigation of minocycline in MS...
  14. ncbi request reprint Interferon beta-1 a and depression in relapsing-remitting multiple sclerosis: an analysis of depression data from the PRISMS clinical trial
    S B Patten
    Department of Community Health Sciences, University of Calgary, Alberta, Canada
    Mult Scler 7:243-8. 2001
    ..6%. However, no evidence of increased depressive symptomatology was observed in association with interferon beta-1a (Rebif)...
  15. ncbi request reprint Short term predictors of unemployment in multiple sclerosis patients
    K D Busche
    Department of Clinical Neurosciences, University of Calgary, Calgary, AB, Canada
    Can J Neurol Sci 30:137-42. 2003
    ..This study determined variables associated with unemployment and risk factors for the development of unemployment in people with MS...
  16. ncbi request reprint Cytokine production in T lymphocyte-microglia interaction is attenuated by glatiramer acetate: a mechanism for therapeutic efficacy in multiple sclerosis
    S Chabot
    Department of Clinical Neurosciences, Faculty of Medicine, University of Calgary, Alberta, Canada
    Mult Scler 8:299-306. 2002
    ..The net result of a non-inflammatory milieu within the CNS, in spite of T cell infiltration, may help account for the amelioration of disease activity in MS patients on glatiramer acetate therapy...
  17. ncbi request reprint The bioavailability of IV methylprednisolone and oral prednisone in multiple sclerosis
    S A Morrow
    Department of Clinical Neurosciences, University of Western Ontario, London, Ontario, Canada
    Neurology 63:1079-80. 2004
    ..122). This suggests that the amount of absorbed corticosteroid is similar after either steroid at these doses...
  18. ncbi request reprint High dose oral steroids commonly used to treat relapses in Canadian MS clinics
    S A Morrow
    Department of Clinical Neurosciences, University of Western Ontario, London, Ontario, Canada
    Can J Neurol Sci 36:213-5. 2009
    ..Recent studies support similarities in the bioequivalence and in the clinical effect of high dose oral corticosteroids for MS relapses...
  19. ncbi request reprint Reliability of visual temporal thresholds
    L N Brown
    Department of Clinical Neurosciences, University of Calgary, Calgary, AB, Canada
    Can J Neurol Sci 34:433-7. 2007
    ..measurements of the temporal aspects in visual processing) are typically significantly higher (i.e., prolonged) in MS patients when compared to controls. The test-retest reliability of these thresholds was examined in patients with MS...
  20. ncbi request reprint Deep grey matter "black T2" on 3 tesla magnetic resonance imaging correlates with disability in multiple sclerosis
    Y Zhang
    Department of Radiology, University of Calgary, Calgary, Canada
    Mult Scler 13:880-3. 2007
    ..5, P < 0.05). BT2 at 3 T may be a useful MRI measure associated with disability in MS and warrants further study...
  21. ncbi request reprint Retinal nerve fiber layer and future risk of multiple sclerosis
    Fiona Costello
    Hotchkiss Brain Institute, University of Calgary, Department of Clinical Neurosciences, Calgary, Alberta, Canada
    Can J Neurol Sci 35:482-7. 2008
    ..The purpose of this study was to determine whether RNFL measurements obtained within two years of an optic neuritis (ON) event distinguish patients at increased risk of developing clinically-definite MS (CDMS)...
  22. ncbi request reprint Predictive value of the CES-D in detecting depression among candidates for disease-modifying multiple sclerosis treatment
    Rupang Pandya
    Psychiatry Administration, Department of Psychiatry, University of Calgary, 1403 29th St, NW, Calgary, ALB T3H 2R9, Canada
    Psychosomatics 46:131-4. 2005
    ..5% (N=38) were found to have a depressive disorder. The results of the study indicate that case-finding for depressive disorders among multiple sclerosis patients can be facilitated by use of the CES-D scale...
  23. doi request reprint Association of alpha-synuclein immunoreactivity with inflammatory activity in multiple sclerosis lesions
    Jian Qiang Lu
    Department of Pathology and Laboratory Medicine, University of Calgary, Alberta, Canada
    J Neuropathol Exp Neurol 68:179-89. 2009
    ..The results suggest that alpha-synuclein expression regulated by inflammatory signals may contribute to neurodegenerative processes in MS lesions...
  24. doi request reprint Continued disease activity in a patient with multiple sclerosis after allogeneic hematopoietic cell transplantation
    Jian Qiang Lu
    Department of Pathology, Foothills Medical Centre, University of Calgary, 1403 29th St NW, Calgary, Alberta T2N 2T9, Canada
    Arch Neurol 66:116-20. 2009
    ..To examine the effect of allogeneic hematopoietic cell transplantation (HCT) on disease activity in a patient with multiple sclerosis (MS)...
  25. ncbi request reprint Cannabis use as described by people with multiple sclerosis
    S A Page
    Office of Medical Bioethics, University of Calgary, Calgary, AB, Canada
    Can J Neurol Sci 30:201-5. 2003
    ..The present study was undertaken to describe cannabis use by this patient group. Information on peoples' beliefs, practices and experiences related to use were investigated...
  26. ncbi request reprint Diminished adenosine A1 receptor expression on macrophages in brain and blood of patients with multiple sclerosis
    J B Johnston
    Department of Clinical Neurosciences, University of Calgary, Alberta, Canada
    Ann Neurol 49:650-8. 2001
    ..Reduction of the A1AR-beta transcript in MS patients suggests that dysregulated splicing may influence A1AR protein levels, potentially leading to increased macrophage activation and central nervous system inflammation...
  27. doi request reprint Dose comparison trial of sustained-release fampridine in multiple sclerosis
    A D Goodman
    Multiple Sclerosis Center, Chief Neuroimmunology Unit, Department of Neurology, University of Rochester Medical Center, 601 Elmwood Ave, Room 6 8521, Box 605, Rochester, NY 14642, USA
    Neurology 71:1134-41. 2008
    ..To examine the efficacy and safety of three different doses of sustained-release fampridine in people with multiple sclerosis (MS)...
  28. ncbi request reprint Glatiramer acetate therapy for multiple sclerosis: a review
    Jai Perumal
    Wayne State University School of Medicine, Department of Neurology, 8D UHC, Detroit, MI 48201, USA
    Expert Opin Drug Metab Toxicol 2:1019-29. 2006
    ....
  29. ncbi request reprint Time for a population based approach to multiple sclerosis care
    Luanne Metz
    Can J Neurol Sci 34:120. 2007
  30. ncbi request reprint Corticosteroids for multiple sclerosis: I. Application for treating exacerbations
    Elliot M Frohman
    Department of Neurology, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas 75235, USA
    Neurotherapeutics 4:618-26. 2007
    ..This review discusses the pharmacology of these agents, to better understand how they may act to mitigate attacks and to provide some practical formulations for how to use them in the clinic for the benefit of patients...
  31. ncbi request reprint Immunogenicity and tolerability of an investigational formulation of interferon-beta1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosis
    Gavin Giovannoni
    Neuroimmunology Unit, Institute of Cell and Molecular Science, Queen Mary University London, London, United Kingdom
    Clin Ther 29:1128-45. 2007
    ..It was developed with the aim of maximizing the treatment benefit for patients with multiple sclerosis (MS) by improving injection tolerability and reducing the development of neutralizing antibodies (NAbs)...